miscarriage%20-%20spontaneous
MISCARRIAGE - SPONTANEOUS

Spontaneous miscarriage is the loss of fetus before 20 weeks of gestation or delivery of a fetus weighing <500 g, in the absence of elective medical or surgical measures to terminate pregnancy.
Early loss is considered if it occurred before menstrual week 12 while late loss refers to those that occurred from menstrual week 12-20.
It is also known as spontaneous abortion, spontaneous pregnancy loss or early pregnancy failure.

Patient Education

  • Bed Rest
    • Encouraged but further study that will show its value in preventing miscarriage is needed
  • Counseling
    • Physician should provide psychological or psychiatric support to the patient
    • Further intervention measures should be based on the patient and her partner’s expectations, coping mechanisms and support systems

Lifestyle Modification

  • Advise the patient to stop smoking, decrease caffeine and alcohol consumption, and to lose weight
    • These factors may be associated with sporadic miscarriage, but relationship with recurrent miscarriage is still uncertain and needs further study
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Harriet Pugsley, MB ChB, MRCOG; Judith Moore, MRCOG, 01 Aug 2013

Most women presenting with complications in early pregnancy are assessed, diagnosed and managed at early pregnancy assessment units (EPAUs). These units aim to provide thorough assessments, access to specialist investigations (scan, human chorionic gonadotrophin [hCG]), a rapid turnaround of results, and co-ordination of further management.

07 Aug 2016
Pravastatin supplementation is associated with improved pregnancy outcomes among women with refractory obstetric antiphospholipid syndrome (APS) who developed preeclampsia (PE) or intrauterine growth restriction (IUGR) during standard antithrombotic therapy, according to a study.
Roshini Claire Anthony, 07 Sep 2016

Estrogen receptor α (ESR1) mutations Y537S and D538G are associated with reduced overall survival (OS) in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, according to findings of a secondary analysis of the BOLERO-2* clinical trial.